Form D · Other Health Care

CRISPR Therapeutics AG

Zug, V8 · CIK 0001674416

Offering snapshot reported Apr 10, 2020 · SEC filing

Reported sold: $1M
Investors reported: 1
Minimum accepted: $0
First sale: Mar 11, 2020

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Apr 10, 2020	Amendment	$1,000,000	$0vs Apr 9, 2020	1	SEC filing
Apr 9, 2020	Initial	$1,000,000	No comparison	1	SEC filing
Nov 4, 2016	Initial	$35,000,000	No comparison	1	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-364701

Source: Form D, filed Apr 10, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Marc Becker	Executive
Ali Behbahani	Director
Bradley Bolzon	Director
Pablo Cagnoni	Director
N. Anthony Coles	Director
Tyler Dylan Hyde	Executive
Simeon George	Director
John Greene	Director
Katherine High	Director
Tony Ho	Executive
James Kasinger	Executive
Lawrence Klein	Executive
Samarth Kulkarni	Director, Executive
Sven Ante Lundberg	Executive
Rodger Novak	Director, Executive
Kala Subramanian	Executive
Michael Tomsicek	Executive
Kurt Von Emster	Director
Thomas Woiwode	Director

Issuer details

Industry: Other Health Care (See others in industry)

Address:

Baarerstrasse 14
Zug, V8, 6300